CAMP4 Therapeutics (NASDAQ:CAMP) CFO Buys 6,551 Shares of Stock

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) CFO Kelly Gold purchased 6,551 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was bought at an average cost of $1.65 per share, for a total transaction of $10,809.15. Following the acquisition, the chief financial officer owned 74,428 shares in the company, valued at approximately $122,806.20. The trade was a 9.65% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

CAMP4 Therapeutics Trading Down 3.6%

CAMP traded down $0.15 during trading on Wednesday, reaching $4.01. 86,050 shares of the company were exchanged, compared to its average volume of 176,472. The stock has a market cap of $208.24 million, a P/E ratio of -1.70 and a beta of 0.22. The firm has a 50 day moving average of $4.02 and a 200 day moving average of $4.31. CAMP4 Therapeutics Corporation has a 52 week low of $1.32 and a 52 week high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last issued its earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.11). The company had revenue of $1.29 million during the quarter. CAMP4 Therapeutics had a negative return on equity of 194.74% and a negative net margin of 2,193.72%. As a group, analysts forecast that CAMP4 Therapeutics Corporation will post -0.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on CAMP. Weiss Ratings downgraded shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 21st. JPMorgan Chase & Co. upgraded shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $5.00 to $9.00 in a research report on Tuesday, June 16th. Chardan Capital set a $6.50 price target on shares of CAMP4 Therapeutics and gave the company a “buy” rating in a research note on Wednesday, June 10th. Zacks Research cut CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 15th. Finally, Rodman & Renshaw began coverage on shares of CAMP4 Therapeutics in a report on Tuesday, April 14th. They issued a “buy” rating and a $7.00 price objective for the company. Seven analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $8.36.

Hedge Funds Weigh In On CAMP4 Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Vivo Capital LLC purchased a new position in shares of CAMP4 Therapeutics in the third quarter worth approximately $11,765,000. Balyasny Asset Management L.P. purchased a new stake in CAMP4 Therapeutics in the 4th quarter worth approximately $14,938,000. Janus Henderson Group PLC boosted its position in CAMP4 Therapeutics by 35.9% during the fourth quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider’s stock valued at $38,807,000 after purchasing an additional 1,666,666 shares during the last quarter. SummitTX Capital L.P. bought a new stake in shares of CAMP4 Therapeutics in the 1st quarter valued at approximately $1,497,000. Finally, EcoR1 Capital LLC bought a new stake in CAMP4 Therapeutics in the fourth quarter worth approximately $1,992,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.